From With $55M, Neon Wants To Make the Cancer Vaccine “Problem” Personal:

Cary Pfeffer, Third Rock Ventures partner and interim CEO, Neon Therapeutics
Cary Pfeffer, Third Rock Ventures partner and interim CEO, Neon Therapeutics

Cary Pfeffer, Third Rock Ventures partner and interim CEO, Neon Therapeutics